Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients

Cephalalgia. 1996 Aug;16(5):337-40. doi: 10.1046/j.1468-2982.1996.1605337.x.

Abstract

Various open and controlled studies have confirmed the antimigraine action of flunarizine, while the antimigraine properties of nimodipine are still open to controversy. Moreover, only a few studies include an additional follow-up after discontinuation of migraine prophylaxis with either drug. We carried out a single blind evaluation of the efficacy and tolerance of flunarizine (25 patients) in comparison with nimodipine (25 patients) and the long-term effect after discontinuation of a 6-month treatment. Both medications significantly reduced migraine frequently and severity. Flunarizine was more efficacious than nimodipine in reducing migraine frequency (p < 0.001), pain severity (p < 0.05), migraine index (p < 0.05) and corrected migraine index (p < 0.05). The positive effect lasted 8.4 +/- 4.0 months after discontinuation of flunarizine and 4.9 +/- 3.5 months after nimodipine (p < 0.05). Our results suggest that flunarizine is more effective than nimodipine in the prophylactic treatment of migraine. The positive effect after drug discontinuation lasts longer with flunarizine, compared to nimodipine.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / therapeutic use*
  • Female
  • Flunarizine / administration & dosage
  • Flunarizine / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Male
  • Migraine Disorders / epidemiology
  • Migraine Disorders / prevention & control*
  • Nimodipine / administration & dosage
  • Nimodipine / therapeutic use*
  • Severity of Illness Index
  • Single-Blind Method
  • Time Factors
  • Treatment Outcome
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / therapeutic use*

Substances

  • Calcium Channel Blockers
  • Vasodilator Agents
  • Nimodipine
  • Flunarizine